GNMSF
Price:
$264.84
Market Cap:
$105.67B
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating sol...[Read more]
Industry
Biotechnology
IPO Date
2010-01-05
Stock Exchange
OTC
Ticker
GNMSF
According to Genmab A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 130.12B. This represents a change of 25.24% compared to the average of 103.90B of the last 4 quarters.
The mean historical Enterprise Value of Genmab A/S over the last ten years is 114.99B. The current 130.12B Enterprise Value has changed 11.22% with respect to the historical average. Over the past ten years (40 quarters), GNMSF's Enterprise Value was at its highest in in the December 2022 quarter at 182.96B. The Enterprise Value was at its lowest in in the March 2016 quarter at 54.41B.
Average
114.99B
Median
108.28B
Minimum
62.24B
Maximum
183.01B
Discovering the peaks and valleys of Genmab A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 71.66%
Maximum Annual Enterprise Value = 183.01B
Minimum Annual Increase = -30.80%
Minimum Annual Enterprise Value = 62.24B
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 150.43B | 71.66% |
| 2024 | 87.64B | -30.80% |
| 2023 | 126.65B | -30.80% |
| 2022 | 183.01B | 11.96% |
| 2021 | 163.46B | 6.42% |
| 2020 | 153.59B | 70.83% |
| 2019 | 89.91B | 44.46% |
| 2018 | 62.24B | -1.24% |
| 2017 | 63.01B | -9.89% |
| 2016 | 69.93B | 32.39% |
The current Enterprise Value of Genmab A/S (GNMSF) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
121.57B
5-year avg
142.24B
10-year avg
114.99B
Genmab A/S’s Enterprise Value is greater than WuXi Biologics (Cayman) Inc. (123.32B), greater than WuXi Biologics (Cayman) Inc. (123.32B), greater than Innovent Biologics, Inc. (121.21B), greater than Sino Biopharmaceutical Limited (88.00B), greater than Sino Biopharmaceutical Limited (88.00B), less than Astellas Pharma Inc. (4.77T), less than Astellas Pharma Inc. (4.77T), greater than Orion Oyj (10.08B), greater than Grifols, S.A. (15.15B), greater than bioMérieux S.A. (11.07B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 123.32B | $21.67B | |
| 123.32B | $17.98B | |
| 121.21B | $18.48B | |
| 88.00B | $15.78B | |
| 88.00B | $14.85B | |
| 4.77T | $26.64B | |
| 4.77T | $28.30B | |
| 10.08B | $21.77B | |
| 15.15B | $16.95B | |
| 11.07B | $12.88B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genmab A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genmab A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Genmab A/S's Enterprise Value?
What is the highest Enterprise Value for Genmab A/S (GNMSF)?
What is the 3-year average Enterprise Value for Genmab A/S (GNMSF)?
What is the 5-year average Enterprise Value for Genmab A/S (GNMSF)?
How does the current Enterprise Value for Genmab A/S (GNMSF) compare to its historical average?